ARCHIVES

FDA, ASCO Meet to Review Drug Approval Endpoints

This article is from The Cancer Letter archive.

Vol. 29 No. 17 | April 25, 2003

Download PDF Visit The Full Archive

Related Articles

Questions Still Surround 88 BCDDP Patients Found With Minimal Cancer; DCCR Asks for Another Review

October 28, 1977

Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer

February 25, 2011

Publications: The Cigarette Papers Available On the Web

September 27, 1996

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

March 28, 2014

Estrogen-Only HRT Little Risk In Endometrial Cancer, GOG Study Indicates

March 26, 2004

NCI Advisory Group, Other Cancer Meetings

July 29, 1983